Carvedilol Plus NUC for Patients With HBV-Compensated Cirrhosis Under Virological Suppression: A Randomized Open-Label Trial

医学 胃肠病学 卡维地洛 肝硬化 内科学 失代偿 肝细胞癌 置信区间 食管静脉曲张 随机对照试验 门脉高压 心力衰竭
作者
Bingqiong Wang,Jialing Zhou,Xiaoning Wu,Yameng Sun,Lei Li,Ping Li,Minghui Li,Wei Jiang,Mingyi Xu,Bo Feng,Xiaoyuan Xu,Jilin Cheng,Wen Xie,Tao Han,Xiaozhong Wang,Hai Li,Hongxin Piao,Xinyu Zhao,Shuyan Chen,Tongtong Meng
出处
期刊:The American Journal of Gastroenterology [Lippincott Williams & Wilkins]
卷期号:119 (4): 700-711 被引量:4
标识
DOI:10.14309/ajg.0000000000002569
摘要

INTRODUCTION: Portal hypertension progression can be relieved after controlling the etiology of liver cirrhosis. Whether beta-blockers could additionally enhance the effects during treatment, particularly for small esophageal varices (EV), was unclear. This study aims to assess the efficacy of add-on carvedilol to delay EV progression during anti-hepatitis B virus (HBV) treatment in HBV-related cirrhosis. METHODS: This randomized controlled trial enrolled patients with virologically suppressed HBV-compensated cirrhosis and small/medium EV. The participants were randomly assigned to receive nucleos(t)ide analog (NUC) or carvedilol 12.5 mg plus NUC (1:1 allocation ratio). The primary end point was the progression rate of EV at 2 years of follow-up. RESULTS: A total of 238 patients (small EV, 77.3%) were randomized into 119 NUC and 119 carvedilol plus NUC (carvedilol [CARV] combination group). Among them, 205 patients (86.1%) completed paired endoscopies. EV progression rate was 15.5% (16/103) in the NUC group and 12.7% (13/102) in the CARV combination group (relative risk = 0.79, 95% confidence interval 0.36-1.75, P = 0.567). Subgroup analysis on medium EV showed the CARV combination group had a more favorable effect in promoting EV regression (43.5% vs 13.1%, P = 0.022) than NUC alone, but not in small cases ( P = 0.534). The incidence of liver-related events (decompensation, hepatocellular carcinoma, or death/liver transplantation) within 2 years was similar between the 2 groups (11.2% vs 10.4%, P = 0.881). DISCUSSION: The overall results did not show statistically significant differences between the added carvedilol strategy and NUC monotherapy in preventing EV progression in patients with virologically suppressed HBV-compensated cirrhosis. However, the carvedilol-added approach might offer improved outcomes specifically for patients with medium EV (NCT03736265).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
NAZZ完成签到,获得积分10
1秒前
豆花鱼发布了新的文献求助20
2秒前
莓莓发布了新的文献求助10
2秒前
trx关闭了trx的文献求助
2秒前
小猫挠屁股完成签到 ,获得积分10
2秒前
科目三的应助被小杨肖恩采纳,获得10
2秒前
3秒前
ZZK020917完成签到,获得积分10
3秒前
3秒前
4秒前
852的应助被爱在日月明采纳,获得10
4秒前
Ccc完成签到,获得积分10
4秒前
6秒前
sa完成签到 ,获得积分10
7秒前
云有心关注了科研通微信公众号
8秒前
WR完成签到,获得积分20
9秒前
冰棍发布了新的文献求助10
10秒前
10秒前
yilin发布了新的文献求助10
10秒前
12秒前
QJY完成签到,获得积分10
12秒前
多情夏柳完成签到,获得积分10
13秒前
Tsuki完成签到,获得积分10
13秒前
LZY完成签到,获得积分10
15秒前
CAO完成签到,获得积分10
15秒前
香蕉觅云的应助被梁三柏采纳,获得10
15秒前
17秒前
17秒前
17秒前
哎呦喂完成签到,获得积分10
18秒前
科研通AI6.3的应助被炸薯条采纳,获得10
18秒前
华仔的应助被风继续吹采纳,获得10
18秒前
冰棍完成签到,获得积分10
20秒前
20秒前
20秒前
丑角苏发布了新的文献求助10
20秒前
20秒前
CipherSage的应助被亚米采纳,获得10
22秒前
22秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181408
求助须知:如何正确求助?哪些是违规求助? 9571330
关于积分的说明 21817615
捐赠科研通 7777856
什么是DOI,文献DOI怎么找? 3433479
关于科研通互助平台的介绍 2557696
邀请新用户注册赠送积分活动 2479527